Radiopharm Theranostics (RADX) Debt to Equity (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Debt to Equity for 2 consecutive years, with $0.75 as the latest value for Q2 2025.
- On a quarterly basis, Debt to Equity fell 38.73% to $0.75 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.75, a 38.73% decrease, with the full-year FY2025 number at $0.75, down 38.73% from a year prior.
- Debt to Equity was $0.75 for Q2 2025 at Radiopharm Theranostics, down from $1.22 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.22 in Q2 2024 to a low of $0.75 in Q2 2025.